Quince Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
QNCX Nasdaq 2834 www.quincetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quince Therapeutics, Inc.

Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital - Dec 16th, 2025 7:26 am
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Dec 15th, 2025 6:00 am
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Dec 10th, 2025 2:05 pm
Quince Therapeutics to Participate at Investor Events in December 2025 - Nov 24th, 2025 6:00 am
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - Nov 12th, 2025 2:05 pm
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Nov 10th, 2025 2:05 pm
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting - Oct 9th, 2025 2:05 pm
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study - Sep 25th, 2025 2:05 pm
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 - Sep 11th, 2025 2:05 pm
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 2:05 pm
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Aug 11th, 2025 2:05 pm
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP - Aug 7th, 2025 6:00 am
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Jul 16th, 2025 6:00 am
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board - Jul 10th, 2025 2:05 pm
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference - Jun 25th, 2025 2:05 pm
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - Jun 18th, 2025 2:05 pm
June 2025's Promising Penny Stocks For Savvy Investors - Jun 16th, 2025 12:04 pm
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - Jun 12th, 2025 3:15 pm
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Jun 3rd, 2025 2:05 pm
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - May 13th, 2025 6:00 am